Send this to a friend

U.S. trade regulators to examine Boston Scientific's $4.2B buy

U.S. trade regulators want a closer look at Marlborough medical device firm Boston Scientific's proposed $4.2-billion acquisition of BTG, a U.K. cancer and vascular disease device firm. 
In a filing with the U.S. Securities & Exchange Commission, Boston Scientific said the U.S. Federal Trade Commission have sent a request for additional information and documentary material relating to the transaction. 

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

ADVERTISEMENTS
Copyright 2017 New England Business Media